• About
• Links
• Contact
• Sitemap

Sitemap > News > Cardiovascular Disorders

• Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
• Cardiome and Astellas Announce Positive Results from ACT 2 Trial
• Scios Announces Enrollment of First Patients In Ascend-HF Trial in Acute Heart Failure
• Archemix Announces Completion of Phase 1 Trial of ARC1779
• Pivotal phase III trial showed RevoladeTM (eltrombopag) raised platelet counts and reduced bleeding in patients with chronic ITP
• Pilot Phase 3 Results of NovaCardia’s KW-3902 for Acute Congestive Heart Failure Presented
• Prexige® study shows significantly less impact on blood pressure than ibuprofen in osteoarthritis patients with controlled hypertension
• FDA Issues Third Approvable Letter for Thelin (Sitaxsentan Sodium)
• Novo Nordisk and Neose announce initiation of phase 1 clinical trial of long-acting factor VIIa
• Exforge receives final US approval as new and powerful treatment option for patients with high blood pressure
• ALEXION’S SOLIRIS GRANTED MARKETING APPROVAL IN EUROPE FOR TREATMENT OF ALL PATIENTS WITH PNH
• Sandoz receives positive EU opinion for approval of epoetin alfa biosimilar
• Rasilez®, an important new treatment for high blood pressure, receives positive opinion recommending European Union approval
• Shire Demonstrates Commitment To Improving Patient Adherence In End Stage Renal Disease As New Phosphate-Binder FOSRENOL® Launches In Europe
• BYETTA® Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
• Benicar HCT Reductions in seated systolic blood pressure for Stage 2 patients compared with Amlodipine benazepril
• Amlodipine and Olmesartan Study Results Released
• Orexigen™ Therapeutics Reports Contrave™ Has Positive Effect on Visceral Fat and Insulin Resistance, Factors Believed to Contribute to the Risk of Heart Disease and Type II Diabetes
• GlaxoSmithKline’s Arixtra® (fondaparinux sodium) receives positive opinion in Europe for the treatment of acute coronary syndromes
• Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R &D Event
• Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
• Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
• Vasogen Reports on Outcome of FDA Meeting
• SPEEDEL REPORTS SUCCESSFUL SPP635 PHASE IIA TRIAL IN HYPERTENSION
• Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
• Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Hypertension
• Ablynx announces interim results of first Nanobody® Phase I study of ALX-0081 (anti-vWF)
• Biogen Idec and Cardiokine partner to develop Lixivaptan, a novel vasopressin antagonist
• Anthera Completes Enrollment of "PLASMA" Trial With A-002 and Announces Initiation of new Investigator Study
• Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
• ProMetic reports positive preliminary phase Ib/II data for PBI-1402 in chemotherapy-induced anemia
• CardioVascular BioTherapeutics Authorized to Initiate Phase II Trial of Angiogenesis Therapy for Severe Coronary Heart Disease
• ProMetic reports positive preliminary phase Ib/II data for PBI-1402 in chemotherapy-induced anemia
• Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
• NicOx receives €5 million milestone from Merck & Co., Inc. as drug candidate enters clinic
• Amira Pharmaceuticals Announces Positive Initial Data from a Phase 1 Study of AM103, A Novel Product Candidate for the Treatment of Respiratory and Cardiovascular Disease
• St. Jude Medical Announces Japanese Approval of CRT-D Products to Treat Heart Failure Patients
• Data Show Overlapping CYPHER® Sirolimus-eluting Coronary Stents Have Better Rates Of Key Clinical Indicators Than Overlapping Bare Metal Stents
• Abbott Enrolls First Patient in World’s First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
• Arena Pharmaceuticals Initiates Phase 1 Clinical Trial Program of APD791 for the Treatment of Arterial Thrombosis
• FDA Grants Fast Track Designation to Cardium's Phase 3 Angiogenic Gene Therapy for Heart Disease
• New data show Tekturna and Diovan used together provide additive blood pressure reductions
• Boston Scientific Announces First Implant of TAXUS Element Platinum Chromium Stent
• Mircera approved in European Union for treatment of anaemia related to chronic kidney disease
• Pervasis Therapeutics Successfully Completes Enrollment for Vascugel Phase II Clinical Trials
• Artisan Pharma, Inc. Launches Phase 2b Trial of ART-123 for Treatment of DIC in Sepsis
• Medicure Announces Second Successful DSMB Review for the Phase 3 Mend-CABG II Trial
• Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
• AtheroGenics Announces First Patients Enrolled in ANDES Phase III Diabetes Clinical Trial
• OMRIX Biopharmaceuticals Receives Food and Drug Administration (FDA) Approval for Thrombin Stand Alone, EVITHROM* Thrombin, Topical (Human), with General Hemostasis in Surgery Indication
• Cardiome and Astellas Announce Regulatory Extension
• Takeda’s Investigational Compound TAK-536 for Treatment of Hypertension Enters into Phase 2 Clinical Stage in Japan
• New Study Findings Confirm CLEXANE®/LOVENOX® Long-Term Clinical Benefit In Patients Suffering From Acute Coronary Syndrome
• Study shows Rasilez®, the first and only approved direct renin inhibitor, reduces a marker of heart failure severity and is well-tolerated
• GTC Obtains FDA Fast Track Designation for ATryn® and Permission to Submit a Rolling BLA
• TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS® Drug-eluting Stent in Women
• Encysive Pharmaceuticals Announces Completion of Patient Enrollment in Phase II Diastolic Heart Failure Trial
• ThromboGenics and BioInvent announce successful completion of phase I trial with TB-402
• Encysive Pharmaceuticals Receives Written Response From FDA On Its Request for Formal Dispute Resolution for THELIN (Sitaxsentan Sodium)
• Aranesp Study Showing No Negative Impact on Survival in SCLC
• Neose Announces Initiation of Phase II Renal Trial of NE-180
• Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema
• FDA Advisory Committees Recommend Continued US Marketing Authorization for Trasylol
• Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
• FDA Accepts NDA Filing for Cleviprex(TM) (Clevidipine Butyrate Injectable Emulsion) for the Treatment of Acute Hypertension
• Study Shows Medtronic Neurostimulation Therapy Improves Chronic Neuropathic Leg and Back Pain
• SYGNIS’ AX200 shows efficacy in stroke patients – Phase IIa results exceed expectations
• Vasogen Plans Confirmatory Study of Celacade™ in Chronic Heart Failure to Support U.S. Regulatory Approval
• Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
• MEDICURE ANNOUNCES COMPLETION OF ENROLLMENT IN PIVOTAL PHASE 3 MEND-CABG II TRIAL
• Phase 2 Study Suggests That Extended Dosing of Aranesp(R) is as Efficacious as Weekly Dosing
• Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp(R)
• CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
• CardioVascular BioTherapeutics Completes Phase I Wound Healing Trial
• Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
• GENFIT launches two Phase II clinical trials for GFT505
• Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
• deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
• deCODE Launches deCODE MI™ - A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
• Pharming Receives Orphan Drug Designation For Recombinant Fibrinogen From FDA
• Hospira\'s Biosimilar Epoetin Retacrit™ Receives Positive Opinion Recommending EU Approval
• Sorin Group announces the first U.S. clinical implant of OVATIO™ CRT
• Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study
• Abbott Announces Positive One-Year Results from the World\'s First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
• Abbott\'s XIENCE™ V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
• ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
• Positive Five-Year Safety Data for TAXUS® Stent Reported in Boston Scientific Trial
• Boston Scientific\'s Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
• Boston Scientific PROMUS™ and TAXUS® Stents Continue Strong Performance in Safety and Efficacy Measures
• ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS® Stent in Complex Real-World Patients
• Elixir Medical Announces Positive Clinical Results for the Company\'s First Drug Eluting Coronary Stent
• New Long-Term Data Suggest Clinical Differences In Safety And Efficacy Between CYPHER® Sirolimus-eluting Coronary Stent And Taxus Stent
• New Study Shows Excellent Outcomes For CYPHER® Sirolimus-eluting Coronary Stent In Treatment Of Completely Blocked Coronary Arteries
• XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
• Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
• Cleviprex(TM) (Clevidipine Butyrate) Rapidly Reduced Blood Pressure and Maintained Control in Study of Patients with Acute Hypertension
• Edwards\' Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
• Gilead Announces New Letairis(TM) (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
• Medtronic Trials Confirm Ability of Interceptor® Coronary Filter System and Export® Aspiration Catheter to Reduce Major Cardiac Events
• Angiomax(R) / Angiox(R) (bivalirudin) Significantly Improved Net Outcomes in Heart Attack Patients
• First U.S. Patients Receive Transoma Medical\'s Sleuth™ Wireless Remote Implantable ECG Monitoring System
• VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
• Bayer HealthCare Submits Rivaroxaban for European Approval
• Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
• Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced
• Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
• In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
• Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
• Arête Therapeutics Initiates Phase 1 Clinical Trial for AR9281 as a First-in-class Antihypertensive Agent
• Data from Completed Phase 1 Studies of Novel Adenosine A2b Antagonist CVT-6883 Show Safety, Tolerability and Potential Utility in Chronic Pulmonary and Inflammatory Diseases
• Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
• FDA Extends PDUFA Date on New Sular Formulation to 2 January 2008
• SPP100 (TEKTURNA/RASILEZ) DECREASES PROTEINURIA IN DIABETIC PATIENTS
• Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
• Affymax(R) Announces Hematide(TM) Successfully Restores Hemoglobin in Patients with Pure Red Cell Aplasia (PRCA)
• Gentium Provides Clinical Update on Phase III Defibrotide Clinical Program
• Toshiba Introduces faCTor64 Study to Improve Early Diagnosis and Treatment of Coronary Artery Disease in Asymptomatic Diabetics
• St. Jude Medical Announces One-Year Results from MASCOT Trial
• St. Jude Medical Announces Results from RethinQ Clinical Trial
• Presentation of phase IIa results for Cytos Biotechnology\'s hypertension vaccine
• Lipitor Provides Greater Benefit Compared to simvastatin in Patients with a History of Heart Attacks Who Have Had Subsequent Cardiovascular Events
• Post-Stroke Patients Treated with Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function
• GlaxoSmithKline initiates trials of Promacta®/Revolade™ (eltrombopag) to investigate the potential to aid hepatitis C patients in achieving sustained virological response
• Bayer Temporarily Suspends Global Trasylol® Marketing
• Affymax(R) Announces Hematide(TM) Successfully Restores Hemoglobin in Patients with Pure Red Cell Aplasia (PRCA)
• The Results of HIJ-CREATE Study, a Large-scaled Clinical Study of Candesartan with Coronary Artery Disease Patients with Hypertension in Japan
• SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
• FDA Strengthens Boxed Warnings, Approves Other Safety Labeling Changes for Erythropoiesis-Stimulating Agents
• Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
• Commencement of clinical trials for warfarin
• Archemix Announces Initiation of Phase 2a Trial for Aptamer Product Candidate ARC1779 in Patients with Acute Coronary Syndrome
• FDA Approves MIRCERA®: First Renal Anemia Treatment with Monthly Maintenance Dosing
• CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
• FDA Accepts Ranexa(R) sNDA and NDA for Filing
• Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE® (Irbesartan-Hydrochlorothiazide)
• Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE® (irbesartan-hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood Pressure Goals
• Cardiome Initiates Phase 1 Study for GED-aPC
• Positive outcome of drug-drug interaction trial with intravenous iclaprim
• St. Jude Medical Announces FDA Approval of Epic Stented Tissue Valve with Anti-Calcification Technology
• Abbott to Present Comprehensive Safety and Efficacy Data on XIENCE™ V Drug Eluting Stent to FDA Advisory Committee on November 29
• FDA Advisory Committee Recommends Approval of Abbott’s XIENCE™ V Drug Eluting Stent System
• amarin commences first clinical trial in cardiovascular program
• Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
• FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
• Medtronic Files PMA Application for FDA Approval of Talent Abdominal Stent Graft System
• Amgen Announces Interim Results of Aranesp(R) \'\'PREPARE\'\' Study in Breast Cancer Patients
• Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
• THEREGEN COMPLETES ENROLLMENT OF ANGINERA PHASE I SAFETY TRIAL; PREPARES FOR PHASE II SUBMISSION
• Portola Initiates Phase II Clinical Program in Heart Attack Patients with its Novel Antiplatelet Agent, PRT060128
• Gentium Announces Expanded Access Program of Defibrotide for Patients with Severe Veno-Occlusive Disease
• Amgen in Discussions with FDA to Update U.S. Prescribing Information for ESAs
• Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results at the American Society of Hematology Annual Meeting (ASH)
• HEMISPHERX BIOPHARMA RECEIVES NOTICE OF INCOMPLETE NEW DRUG APPLICATION (NDA)
• SPEEDEL ANNOUNCES START OF SPP635 PHASE IIA TRIAL IN DIABETIC PATIENTS
• Phase II Trial of ProMetic’s PBI-1402 Shows Significantly Increased Red Blood Cell Count and Hemoglobin in Chemotherapy-Induced Anemia Patients
• Phase 1 Clinical Trial Starts for RVX-208
• ThromboGenics presents results of Phase I Trial of TB-402 at ASH
• Three Pivotal Phase III Trials Show Superior Efficacy of Rivaroxaban over Standard of Care with Enoxaparin
• GTC Obtains FDA Orphan Drug Designation for ATryn
• Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
• FDA Advisory Committee Recommends Approval of KYNAPID for Acute Atrial Fibrillation
• Medtronic Starts First Human Study of Endurant™ Stent Graft System for Treatment of Abdominal Aortic Aneurysm
• Athersys Receives IND Authorization for MultiStem in Acute Myocardial Infarction
• GlaxoSmithKline files for FDA approval of Promacta/ Revolade (eltrombopag) to be the first oral platelet growth factor for rare blood disorder
• AMAG Pharmaceuticals, Inc. Submits New Drug Application to FDA for Ferumoxytol in Chronic Kidney Disease Patients
• Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
• ImaRx Provides Update on Tucson Phase I/II Clinical Trial In Acute Ischemic Stroke.
• FDA Receives New Data on Risks of Anemia Drugs
• VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
• Baxter Announces Recombinant Factor IX Development Program for Hemophilia B
• Sangart, Inc. Initiates Dosing In Phase II Study Of Hemospan® In Chronic Critical Limb Ischemia
• Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of DG051 for the Prevention of Heart Attack
• NitroMed Reports on BiDil XR(TM) Progress Following FDA Meeting, Announces Restructuring and Suspension of BiDil(R) Sales Force, and Retains Investment Bank to Advise on Strategic Options
• Anthera Announces Preliminary Positive Results from Once-Daily A-002 Phase II Cardiovascular Trial.
• St. Jude Medical Announces FDA and European CE Mark Approvals of Durata Defibrillation Lead
• FDA Approves ZymoGenetics\' RECOTHROM(TM) Thrombin, topical (Recombinant)
• Boehringer Ingelheim announces enrolment completion of the largest atrial fibrillation outcomes trial – The RE-LY Study
• Biosensors receives CE Mark approval for its BioMatrix drug-eluting stent.
• OXIS Out-licensed Drug BXT 51072 to Be Developed by Synvista for the Treatment of Psoriasis
• Nuvelo Announces Alfimeprase NAPA-2 Acute Peripheral Arterial Occlusion Data
• CeloNova BioSciences Introduces a New Class of Coronary
• Cardiome and Astellas Announce Regulatory Update
• Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
• St. Jude Medical Announces FDA and European CE Mark Approval of the QuickFlex Family of Leads
• Abiomed Receives HDE Supplement Approval for AbioCor Artificial Heart
• European Medicines Agency recommends approval of novel oral anticoagulant, dabigatran etexilate (Pradaxa)
• Takeda Doses First Patient in A U.S. Phase 1 Study of Hematide to Treat Chemotherapy Induced Anemia
• Nuvelo Announces Results from Phase 3 NAPA Program in Acute Peripheral Arterial Occlusion
• Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
• Gentium Announces the Data Safety Monitoring Board Review of the Phase III Trial of Defibrotide to Treat Patients with Severe Veno-Occlusive Disease
• Clexane/Lovenox approved in Japan
• Myriad Genetics Announces Completion of Phase 1 Trial of Anti-Thrombin Drug MPC-0920
• AngioScore Obtains Japanese Approval for AngioSculpt Scoring Balloon Catheter
• Archemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Nuvelo
• Medtronic Receives FDA Approval for Endeavor® Zotarolimus-Eluting Coronary Stent System
• Injectafer® (Ferinject®): Recommendation of the FDA Advisory Committee, Recommendation for approval when oral iron treatment is ineffective
• Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
• CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
• Chelsea Therapeutics Begins Patient Dosing
• VGX Pharmaceuticals announces the IND filing of VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia
• Biogen Idec and Cardiokine Initiate Phase III Clinical Trial for Lixivaptan in Congestive Heart Failure Patients with Hyponatremia
• AMAG Pharmaceuticals, Inc. Announces FDA Acceptance for Filing of Ferumoxytol New Drug Application in Chronic Kidney Disease
• Chelsea Therapeutics Receives Special Protocol Assessment for Pivotal Phase 3 Study of Droxidopa in Neurogenic Orthostatic Hypotension
• Sciele and Addrenex Announce NDA Submission of CloniBID to Treat Hypertension
• diaDexus Receives FDA Clearance For Automated Blood Test That Identifies Stroke and Heart Attack Risk
• GSK\'s Volibris (ambrisentan) receives EMEA positive opinion for approval to treat class II and II pulmonary arterial hypertension (PAH)
• Wyeth\'s XYNTHA Approved by FDA for Treatment of Hemophilia A
• Repros\' IND for the Commencement of Phase III Studies of Proellex(R) in the Treatment of Anemia Associated with Uterine Fibroids is Now Effective
• FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel
• ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
• Harvest Technologies announces patient enrollment has begun for a clinical trial in India using autologous adult stem cells to treat patients with non-reconstructible Critical Limb Ischemia (CLI) due to Peripheral Arterial Occlusive Disease (PAOD)
• Artisan Pharma’s Lead Product, ART-123, Approved in Japan
• View Summary Prochymal(TM) Demonstrates Lasting Benefit in Heart Attack Patients; Osiris Receives FDA Clearance to Start Phase II Trial
• Pharmacopeia Completes Enrolment in Phase 2 Hypertension Study with PS433540 (DARA)
• Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business
• Biovitrum and Syntonix set to begin phase I/IIa clinical trial of long-acting recombinant Factor IXFc for the treatment of Hemophilia B
• Vasogen Provides Update on ACCLAIM II Program
• ProMetic reports continued positive data in PBI-1402 Phase II trial in chemotherapy-induced anemia
• EU Commission Approves Updated Prescribing Information for Aranesp
• Independent Data Safety Monitoring Board Recommends Continuation of Sangart’s Pivotal Phase III Trials of Hemospan Following Second Interim Review
• Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study with PL-3994 for the Treatment of Congestive Heart Failure
• Amgen to Discuss Romiplostim Application at FDA ODAC Meeting
• More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
• Medtronic Introduces Improvement to Minimally Invasive Treatment of Aortic Aneurysms in Europe
• FDA Clears bioMérieux’s VIDAS® NT-proBNP
• Amgen Statement on Successful Outcome of Romiplostim Panel Meeting
• Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
• Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
• Abiomed Receives Conditional FDA Approval for Impella 2.5 Study for Acute Myocardial Infarction (AMI) Patients
• Archemix Announces Initiation of Phase 2 Trial for Aptamer Product Candidate ARC1779 in Patients with TTP, a Rare, Life-Threatening Blood Disorder
• Abiomed Receives Conditional FDA Approval for Impella 2.5 Study for Acute Myocardial Infarction (AMI) Patients
• QuantRx® Announces Commencement of Phase I Clinical Trial by FluoroPharma for BFPET™, a Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
• VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
• Medtronic’s New Endeavor® Zotarolimus-Eluting Stent Approved for Patients with Coronary Artery Disease in Canada
• FDA Makes Recommendations on Medical Devices That Treat Blocked Heart Arteries
• OMRIX Biopharmaceuticals Initiates Phase II Clinical Trial for Fibrin Patch Product Candidate
• Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
• TAXUS® Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
• Spirit II Results Support Strength of Boston Scientific\'s Two Drug-Eluting Stent Platforms
• Study Finds Taxus® Drug-Eluting Stent Beneficial in Treatment of Large Vessels
• Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS® Express™ Stent
• 12-Month Data from Endeavor IV Show Strong Clinical Efficacy of Medtronic’s Drug-Eluting Stent Across All Patient Groups
• Novogen cardiovascular drug enters phase I clinical trial
• Merck\'s Investigational Rolofylline Associated with Improved Dyspnea and Preserved Renal Function in Acute Heart Failure Patients in a Phase III Pilot Study
• The FDA Accepts the Complete Response for Clinical Holds of FG-2216*/FG-4592 for the Treatment of Anemia
• VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
• Affymax and Takeda Report Long-Term Safety and Effectiveness Data of Hematide in Chronic Renal Failure Patients With Anemia
• ThromboGenics announces that it has completed patient enrolment for its Phase II MITI IV study
• Synthetic Blood International, Inc. Announces Plans to File Protocol for Phase II-b Oxycyte Clinical Trial
• Aradigm Initiates Trial of Lung Rx\'s Inhaled Treprostinil
• CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
• Medgenics on target to start Phase I/II clinical trials with EPODURE protein therapy for anaemia mid-2008 as planned
• Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
• ORAL PBI-1402 DEMONSTRATES SIGNIFICANT ACTIVITY IN CHEMOTHERAPY-INDUCED ANEMIA PHASE II CLINICAL TRIAL
• FDA Grants Market Clearance for the LipiScan™ Coronary Imaging System Developed By InfraReDx, Inc.
• Acusphere Submits New Drug Application for FDA Approval of Imagify
• Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
• Cytokinetics Announces the Initiation of Second Phase IIa Clinical Trial of CK-1827452
• AngioScore Receives FDA Clearance to Market AngioSculpt PTA Scoring Balloon Catheter for Additional Peripheral Indications
• ZymoGenetics Presents Positive Results from RECOTHROM Thrombin, topical (Recombinant) Spray Study in Burn Patients
• Gilead Initiates Letairis (ambrisentan) Phase IV Program
• Boston Scientific Announces FDA Approval of New Family of Advanced Pacemakers
• Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
• Affymax and Takeda Announce Long-Term Hematide Safety and Effectiveness Data from Phase 2 Clinical Trials in Chronic Kidney Disease Patients with Anemia
• XIENCE™ V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
• St. Jude Medical Announces Start of Landmark DETERMINE ICD Study
• TAXUS® Express® Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
• Thrombus Aspiration Before Stenting Benefits Patients Suffering Myocardial Infarction, Study Shows
• Medtronic Announces FDA Approval of New Vision 3D Wireless Implantable Cardiac Devices
• Endeavor II Four-Year Results Demonstrate Long-Term Safety and Durable Efficacy of Medtronic Drug-Eluting Stent
• St. Jude Medical Announces Launch of New Circular Mapping Catheter
• St. Jude Medical Announces FDA and European CE Mark Approvals of the IsoFlex Optim Pacing Lead
• St. Jude Medical Announces Start of Landmark DETERMINE ICD Study
• SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS™ and TAXUS® Express® Stents
• Boston Scientific Announces FDA Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
• Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
• Terguride receives FDA orphan drug designation for the treatment of pulmonary arterial hypertension
• VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
• SORIN GROUP ANNOUNCES FDA APPROVAL OF THE WORLD’S SMALLEST CARDIAC RESYNCHRONIZATION IMPLANTABLE CARDIOVERTER DEFIBRILLATOR: OVATIO CRT
• Multaq® (dronedarone) - Results of the ATHENA Clinical Trial
• CERENIS THERAPEUTICS COMPLETES PHASE I CLINICAL TRIAL OF CER-002 FOR TREATMENT OF CARDIOVASCULAR DISEASE